Article
Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS).
American journal of hematology - 1 Feb 2006
Rao V Koneti, Carrasquillo Jorge A, Dale Janet K, Bacharach Stephen L, Whatley Millie, Dugan Faith, Tretler Jean, Fleisher Thomas, Puck Jennifer M, Wilson Wyndham, Jaffe Elaine S, Avila Nilo, Chen Clara C, Straus Stephen E
Abstract excerpt
Autoimmune lymphoproliferative syndrome (ALPS) is associated with mutations that impair the activity of lymphocyte apoptosis proteins, leading to chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma. We investigated the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in discriminating benign from malignant lymphadenopathy in ALPS. We report that FDG...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.